Status:

COMPLETED

Optimal Treatment of MRSA Throat Carriers

Lead Sponsor:

Hvidovre University Hospital

Conditions:

MRSA

MRSA Colonization

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The aim of this study is to investigate the optimal way to treat MRSA throat carriers.

Detailed Description

The bacterium Staphylococcus aureus frequently colonizes the human skin and mucous membranes. Longitudinal studies usually divide S. aureus carriers into either persistent or intermittent carriers, bu...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • MRSA carriage in the throat after first topical decolonization treatment (regardless of previous swab results)
  • Has completed one standard topical decolonization treatment

Exclusion

  • Pregnant or lactating woman
  • Sexually active women in the reproductive age that do not use approved contraceptives (appendix 4)
  • Cannot read or speak Danish (the written participant information is in Danish)
  • Skin infection or other active infections
  • Activity in skin diseases such as eczema or psoriasis.
  • MRSA isolate resistant to clindamycin (defined by inhibition zone size \< 22 mm using disk diffusion methodology) or resistant to mupirocin
  • Allergy to clindamycin, chlorhexidine or mupirocin
  • Taking medications that interact with clindamycin according to the medicine information leaflet.
  • MRSA active antibiotic treatment within 7 days before inclusion in the study or during study period
  • Followed by specialist due to liver disease
  • Severe overweight (BMI \> 35) or weight \< 50 kg
  • Indwelling percutaneous permanent devices such as intravenous catheters or urinary tract catheters
  • Daily contact with pigs or minks (decolonization therapy is generally not offered, according to The National Board of Health)
  • Nursing home resident or health care worker (they have a more frequent control swab regime)
  • Not being capable of completing another treatment successfully
  • MRSA positive household members younger than 2 years (MRSA positive children below 2 years of age and their household members are generally not offered decolonization treatment according to The National Board of Health)
  • MRSA positive household members, where it is judged that further decolonization attempts are not indicated

Key Trial Info

Start Date :

May 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 18 2025

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT04104178

Start Date

May 20 2020

End Date

September 18 2025

Last Update

September 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hvidovre Hospital

Hvidovre, Denmark